We from the global health and business community note a major deal: on December 24, 2025, French pharma Sanofi agreed to buy U.S. vaccine maker Dynavax for $2.2 billion. The deal will boost Sanofi’s adult vaccine portfolio and is expected to close in early 2026 after regulatory approvals. Who Is Sanofi? Sanofi is a top…
This week, French healthcare giant Sanofi announced it will buy Dynavax Technologies for $2.2 billion in cash. The all-cash deal values Dynavax above its recent stock price. This is major news in vaccines, especially for adult immunization. Sanofi will gain new products and early-stage vaccine candidates. The acquisition is expected to be completed in early 2026…
Sanofi has achieved a major milestone by securing approval for two innovative bleeding‑disorder treatments in China, as announced recently by the company and local regulators. The Chinese National Medical Products Administration (NMPA) granted approvals for Qfitlia and Cablivi, two specialized medicines designed to treat rare and serious blood disorders, strengthening Sanofi’s presence in one of…